<DOC>
	<DOCNO>NCT00866970</DOCNO>
	<brief_summary>The purpose study asses safety efficacy ALD518 patient Non-Small Cell Lung Cancer-Related Fatigue cachexia ( weight-loss ) .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics ALD518 Patients With Non-Small Cell Lung Cancer-related Fatigue Cachexia</brief_title>
	<detailed_description>This phase II , double-blind , randomize , placebo-controlled study ALD518 patient NSCLC relate fatigue cachexia . It estimate total 120 patient randomize ALD518 80 mg , 160 mg , 320 mg , placebo 1:1:1:1 ratio . A total eight visit ( exclude Screening visit ) take place period 24 week : Day 1 , Weeks 2 , 4 , 8 , 12 , 16 , 20 , 24 . Enrolled patient screen within 4 week period ( Day 35 7 ) . Randomization treatment within 12 day period ( Day 14 3 ) , initial dose Day 1 . Patients receive treatment eight week apart ( Day 1 , Weeks 8 16 ) . All patient remain clinic least 4 hour time infusion start . Follow-up visit occur four eight week last dose study drug , Weeks 20 24 , respectively .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Confirmed diagnosis NSCLC incurable treatment include surgery A ≥5 % loss body weight precede 3 month A Creactive protein ( CRP ) concentration ≥ 10 mg/L Life Expectancy least 12 week Treatment chemotherapy , largefield radiotherapy , surgery treatment cancer past 30 day AST/ALT ≥ 3 x ULN screen Hemoglobin &lt; 8 g/dL Screening History active diagnosis Tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Cachexia</keyword>
</DOC>